

CONTENTS

	<i>Page</i>
Part one. General information	1
Notes	2
Introduction	3
Remarks on the statistical tables	3
English-French-Spanish index of names of countries and non-metropolitan territories	9
English-French-Spanish index of names of narcotic drugs	15
Part two. Comments on the reported statistics on narcotic drugs	19
Notes	20
Comments on the reported statistics on narcotic drugs	21
Part three. Supply of opiate raw materials and demand for opiates for medical and scientific purposes	117
Notes	118
Supply of opiate raw materials and demand for opiates for medical and scientific purposes	119
Part four. Statistical information on narcotic drugs	155
Notes	156
Tables of reported statistics	157
Table I. Cultivation of <i>Papaver somniferum</i> for the production of opium, 2016–2022	169
Table II. Cultivation of <i>Papaver somniferum</i> for purposes other than the production of opium, 2016–2022: production of poppy straw (M, T, C, N and O)	170
Table III. Extraction of alkaloids from opium, 2016–2020	176
Table IV. Extraction of morphine from poppy straw (M), 2016–2020	178
Table V. Extraction of thebaine from poppy straw (T and M), 2016–2020	182
Table VI. Conversion of morphine, 2016–2020	184
Table VII. Conversion of thebaine, 2016–2020	188
Table VIII. Manufacture of alkaloids contained in concentrate of poppy straw, 2016–2020	191
Table IX. Manufacture of the principal narcotic drugs, 2016–2020	194
Table X. Manufacture of other narcotic drugs, 2016–2020	201
1. Derivatives of opium alkaloids	201
2. Synthetic opioids	201
Table XI. Production, utilization, imports and exports of coca leaf and manufacture of cocaine, 2016–2020	202
Table XII. Consumption of the principal narcotic drugs and calculated consumption of buprenorphine, 2016–2020	204
Table XIII. Consumption of other narcotic drugs, 2016–2020	234
1. Fentanyl, principal fentanyl analogues and piritramide	234
2. Other derivatives of opium alkaloids	256
3. Other synthetic opioids	256
Table XIV. Levels of consumption of narcotic drugs, in defined daily doses for statistical purposes per million inhabitants per day, 2018–2020	257
1. Average consumption of narcotic drugs (excluding preparations in Schedule III) and calculated consumption of buprenorphine	257
a. All countries	257
b. Africa	265
c. Asia	267
d. Central America and the Caribbean	270
e. Europe	272
f. North America	274
g. Oceania	275
h. South America	277
i. All regions	278
2. Global average levels of utilization of narcotic drugs for the manufacture of preparations listed in Schedule III, in defined daily doses for statistical purposes per million inhabitants per day, 2011–2020	279
3. Global consumption of opioids, expressed in millions of defined daily doses for statistical purposes (S-DDD) 2001–2020 ..	280
Table XV. Total stocks of narcotic drugs, 2016–2020	282

Annexes*

I. Status of adherence to international conventions on narcotic drugs and receipt of statistics (2020) and estimates (2022)	287
Notes	288
Table	289
II. Estimated requirements of narcotic drugs	299
Notes	300
Table A. Estimated world requirements of narcotic drugs for 2022	302
Table B. World totals of estimates, 2017–2022	342
III. Comparative statement of estimates and statistics for 2020	345
Notes	346
Table	348
IV. World trade, 2018–2020	437
Notes	438
1. Exports of opiate raw materials, 2018–2020	439
2. Imports of opiate raw materials, 2018–2020	441
3. Exports of the principal narcotic drugs, 2018–2020	444
4. Imports of the principal narcotic drugs, 2018–2020	452
V. Seizures of selected narcotic drugs, 2020	475
Notes	476
Table	477

*As of 2018, the CD-Rom is no longer included in the printed version of this report. The report in its entirety, including the annexes, are available on the INCB website (www.incb.org).